Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Posted
Applied Therapeutics, Inc is a biotechnology business based in the US. Applied Therapeutics shares (APLT) are listed on the NASDAQ and all prices are listed in US Dollars. Applied Therapeutics employs 22 staff and has a market cap (total outstanding shares value) of USD$501.5 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$20.44 |
---|---|
52-week range | USD$13.58 - USD$57.39 |
50-day moving average | USD$20.6209 |
200-day moving average | USD$25.4077 |
Wall St. target price | USD$53 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-3.686 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $20.44 from 2020-12-09
1 week (2021-01-07) | -5.76% |
---|---|
1 month (2020-12-17) | -14.30% |
3 months (2020-10-15) | -12.05% |
6 months (2020-07-15) | -33.44% |
1 year (2020-01-15) | -54.14% |
---|---|
2 years (2019-01-13) | N/A |
3 years (2018-01-13) | N/A |
5 years (2016-01-13) | N/A |
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -68.16% |
Return on equity TTM | -131.51% |
Profit margin | 0% |
Book value | $4.584 |
Market capitalisation | USD$501.5 million |
TTM: trailing 12 months
There are currently 1.6 million Applied Therapeutics shares held short by investors – that's known as Applied Therapeutics's "short interest". This figure is 6.1% up from 1.5 million last month.
There are a few different ways that this level of interest in shorting Applied Therapeutics shares can be evaluated.
Applied Therapeutics's "short interest ratio" (SIR) is the quantity of Applied Therapeutics shares currently shorted divided by the average quantity of Applied Therapeutics shares traded daily (recently around 145773.86046512). Applied Therapeutics's SIR currently stands at 10.75. In other words for every 100,000 Applied Therapeutics shares traded daily on the market, roughly 10750 shares are currently held short.
However Applied Therapeutics's short interest can also be evaluated against the total number of Applied Therapeutics shares, or, against the total number of tradable Applied Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Applied Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Applied Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.1141% of the tradable shares (for every 100,000 tradable Applied Therapeutics shares, roughly 114 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Applied Therapeutics.
Find out more about how you can short Applied Therapeutics stock.
We're not expecting Applied Therapeutics to pay a dividend over the next 12 months.
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that is in phase I/II for the treatment of galactosemia; AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy; and AT-003 that is in phase I clinical trial for the treatment diabetic retinopathy. The company's preclinical stage products include AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.